In this study we have addressed the fundamental question of what cellular mechanisms control the growth of the calvarial bones and conversely, what is the fate of the sutural mesenchymal cells when calvarial bones approximate to form a suture. There is evidence that the size of the osteoprogenitor cell population determines the rate of calvarial bone growth. In calvarial cultures we reduced osteoprogenitor cell proliferation; however, we did not observe a reduction in the growth of parietal bone to the same degree. This discrepancy prompted us to study whether suture mesenchymal cells participate in the growth of the parietal bones. We found that mesenchymal cells adjacent to the osteogenic fronts of the parietal bones could differentiate towards the osteoblastic lineage and could become incorporated into the growing bone. Conversely, mid-suture mesenchymal cells did not become incorporated into the bone and remained undifferentiated. Thus mesenchymal cells have different fate depending on their position within the suture. In this study we show that continued proliferation of osteoprogenitors in the osteogenic fronts is the main mechanism for calvarial bone growth, but importantly, we show that suture mesenchyme cells can contribute to calvarial bone growth. These findings help us understand the mechanisms of intramembranous ossification in general, which occurs not only during cranial and facial bone development but also in the surface periosteum of most bones during modeling and remodeling.
Introduction
At a molecular level we have a good understanding of what regulates the commitment of undifferentiated mesenchymal cells into osteoblasts (reviewed by Cohen, 2006; Karsenty, 2003) . We also know a great deal about endochondral ossification and what controls long bone growth which is a complex process involving the formation of a cartilaginous template that is later replaced by bone. Intramembranous bone ossification accounts for most of the bone growth of the face and calvaria and in the periosteum of long bones (Kronenberg, 2003; Ornitz, 2005) . In contrast to endochondral ossification, intramembranous bone ossification is a relatively simple process with no cartilage anlagen and osteoblasts differentiating directly from mesenchymal cells. It is therefore surprising that we know much less about the cellular processes that control intramembranous bone growth compared to the processes controlling endochondral bone growth.
In the craniofacial region, intramembranous bone development starts with the aggregation of mesenchymal cells into condensation centers (Hall and Miyake, 2000) . These tightly packed collections of cells expand and once they reach a critical size the cells at the center of these masses differentiate into osteoblasts. Growth of immature bones occurs at the leading edges or osteogenic fronts and when an osteogenic front confronts its neighbor, the two fronts either merge to create a single bone or form a suture. Thus a suture is a joint composed of two osteogenic fronts and the interposed mesenchyme. Once the basic pattern of bones and sutures has been established further craniofacial growth primarily occurs in the osteogenic fronts of the sutures. The processes of osteogenic condensation formation and function during embryogenesis, to form the first bony elements, are directly comparable to the processes of cell aggregation, proliferation, differentiation and function that occur in the osteogenic fronts of established craniofacial intramembranous bones.
The rate of calvarial bone growth is determined by the size of the osteoprogenitor cell population in the perimeter of the osteogenic condensations and then later by the size of the osteoprogenitor population in the osteogenic fronts. We have previously shown that the transcription factor Foxc1 regulates bone morphogenetic protein (BMP)-mediated osteoprogenitor proliferation, specifically at the leading edge of the developing calvarial bones thus regulating bony expansion. Reduced osteoprogenitor proliferation in Foxc1 −/− mice results in small calvarial bones that do not grow beyond a rudimentary size and remain at the sites of the initial osteogenic condensations. Foxc1 controls the osteoprogenitor population by regulating the BMP targets Msx2 and Alx4 . In both humans and mice, loss-of-function mutations in Msx2 and Alx4 result in similar 'hole in the head' phenotypes to those exhibited by Foxc1 −/− mutant mice (Antonopoulou et al., 2004; Satokata et al., 2000; Wilkie et al., 2000) . Conversely, mice which overexpress Msx2 exhibit increased osteoprogenitor proliferation in osteogenic fronts of the calvarial bones, which results in enhanced bone growth (Liu et al., 1999b) . Consistent with this, a gain-of-function mutation in MSX2 causes Boston-type craniosynostosis in humans which is characterized by excessive calvarial bone growth and an obliteration of the calvarial sutures (Liu et al., 1995) .
In addition to BMP signaling, the size of the calvarial osteoprogenitor population is regulated by fibroblast growth factor (FGF) signaling. Several Fgf ligands and receptors are expressed in the developing calvarial mesenchyme and bones (Hajihosseini and Heath, 2002; Hajihosseini et al., 2001; Rice et al., 2003a) , and targeted disruption of Fgfr signaling in mice results in altered calvarial osteoprogenitor proliferation and abnormal bone growth (Eswarakumar et al., 2004; Eswarakumar et al., 2002; Wang et al., 2005) . It has been proposed that signaling through Fgfr2 primarily regulates osteoprogenitor proliferation while signaling through Fgfr1 primarily regulates osteoblast differentiation (Iseki et al., 1999) . In humans, mutations in FGFR1, 2 and 3 cause several forms of syndromic and non-syndromic craniosynostosis including Apert, Crouzon and Pfeiffer syndromes and Muenke craniosynostosis. All these conditions are characterized by premature craniofacial suture fusion as well as other skeletal anomalies .
We have previously proposed the developing mouse sagittal suture as an uncomplicated model of osteoblastic differentiation and intramembranous bone growth (Rice et al., 2003b) . By analyzing the distribution of markers that are expressed at different stages of osteoblastic differentiation, we can build up a picture of the suture so that we can see all stages of differentiation within a single tissue section. In this study we have expanded and refined this analysis and used it to study calvarial bone growth. We have previously shown that embryonic day 15.5 (E15.5) mouse parietal bones grow towards each other and after 2 days of culture form a normal patent sagittal suture (Kim et al., 1998) . Using this system we now ask the fundamental questions: what are the cellular mechanisms controlling calvarial bone growth; and conversely what is the fate of the calvarial mesenchymal cells when parietal bones approximate and a suture is formed?
In this study we show that proliferation and subsequent differentiation of osteoprogenitors at the osteogenic fronts, although important, is not the only cellular mechanism that contributes to calvarial bone growth. Sutural mesenchymal cells can differentiate into osteoblasts and become incorporated into the growing parietal bones, but only if adjacent to the osteogenic fronts. Thus the fate of calvarial mesenchymal cells varies depending on their position within the suture. Under normal conditions we demonstrate that a small percentage of sutural mesenchymal cells are incorporated into the growing bones. We can hypothesize that during pathological conditions such as craniosynostosis the relative contribution of recruitment from the mesenchyme into the calvarial bones may be altered.
Materials and methods

Organ culture
Calvaria were dissected free from skin and brain from E15.5 mouse embryos. Explants were placed in Nuclepore polycarbonate filters (Whatman) and cultured in a Trowell-type organ culture system for 2 or 5 days depending on the experiment. DMEM (Sigma) was supplemented with 20 IU/ml penicillin/ streptomycin (Sigma), 10% fetal bovine serum (Life Technologies), and 100 μg/ ml of ascorbic acid. Media were replaced every 2 days. The antimitotic drug nocodazole (Sigma-Aldrich) was added to the culture media in different concentrations (0.1 μg/ml, 0.25 μg/ml, and 1.0 μg/ml) from a stock of 0.5 mg nocodazole in 2 ml DMSO. Explants treated with 1 μl of DMSO per 1 ml of media were used as control. At least two explants treated with DMSO as control and two of each nocodazole dilutions were sectioned and at least 4 sections of each explant were used to count BrdU positive cells.
Cell culture
Cells were enzymatically isolated from the calvaria of CD1 mice postnatal day 1 by sequential digestion with trypsin (1 mg/ml), dispase II (2 mg/ml), and two digestions with collagenase A (2 mg/ml) (Roche). The last two of the four digestion steps (populations III-IV) were pooled and plated in T75 flasks containing α-MEM (Sigma), penicillin-streptomycin, glutamine and 15% of heat activated fetal bovine serum (FBS). After 24 h of incubation attached cells were then collected by trypsinization. Aliquots were counted and remaining cells were resuspended in the standard medium described above supplemented with ascorbic acid (50 mg/ml) and 10 mM of β-glycerol phosphate. The resuspended cells were plated in tissue culture dishes at approximately 4 × 10 3 cells/cm 2 . The medium was changed every 2-3 days. Cells were incubated at 37°C in humidified atmosphere at 95% air 5% CO 2 incubator. DMSO (1:50,000) or nocodazole (0.1 μg/ml or 1.0 μg/ml) was added to the media on day 1 on cell culture (experiment 1), when cells had reached confluence (experiment 2) or just when nodule formation was staring to occur (experiment 3). Cells were washed in PBS and then stained for alkaline phosphatase using naphtol-AS-MX phosphate and fast red (Sigma) with 100 mM of Tris pH 8.3.
Vital dye injections
DiI C 18 (1-1′-dioctadecyl-3,3,3′,3′-tetramethilindocarbocyanine perchlorate, Molecular Probes, Inc) was dissolved at 5% in absolute ethanol and then diluted 1:10 in 0.3 M sucrose. CellTracker™CM-DiI (Molecular Probes, Inc) was used for labeling in the same manner. Using microcapillars filled with DiI, microinjections were performed under a stereo microscope on the day 0 of culture. DiI-labeled cells were tracked using an Olympus SZX12 microscope with a fluorescent light by photographing at day 0, day 1 and day 2 of culture.
Explants were fixed after 2 days of culture in 4% paraformaldehyde (PFA) overnight at 4°C. Explants labeled with DiI C 18 were embedded with O.C.T compound (BDH, VWR), stored in −70°C and cryosectioned (7 μm). Explants in which CellTracker™CM-DiI was used were dehydrated in gradient ethanol series, paraffin embedded and sectioned (7 μm). Images of both cryosections and paraffin sections were taken with a Zeiss Axioskop 2 plus coupled with fluorescence light before proceeding with any staining. Hematoxylin and eosin staining or alkaline phosphatase (Roche) (Liu et al., 1999a) staining was performed and images were taken and then superimposed using Adobe Photoshop 6.0 software in order to establish the location and the identity of the labeled cells.
Green fluorescence protein tissue transplantations
Two types of transplantations were performed: sagittal suture mesenchyme transplantations and osteogenic front transplantations. The tissue was dissected from green fluorescence protein expressing mice (chicken beta-actin/CMV enhancer construct) and grafted into CD1 calvarial explants in the exact same position as it was in the donor tissue. The recipient's sagittal suture mesenchyme was removed prior the grafting. The operation was performed in the day 0 of culture, and tissues were cultured for 5 days. Images of the cultures were taken with Olympus SZX12 microscope. Explants were fixed in 4% PFA and processed. Paraffin sections were photographed under fluorescence light before any staining. H&E staining or Bone sialoprotein detection by 35 S in situ hybridization was performed and then superimposed with the florescence images.
BrdU incorporation and TUNEL analysis
Pregnant females were injected i.p. with 2 ml/100 g body weight of 5bromo-2′-deouxyridine (BrdU) solution (Zymed). After 2 h, embryos were collected, fixed in 4% PFA, dehydrated and paraffin embedded for sectioning. Cultured tissues were BrdU pulsed diluting the labeling reagent 1:100 with tissue culture medium. BrdU incorporation was immunodetected by using BrdU staining kit (Zymed). Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay was performed by using the DeadEnd Colorimetric TUNEL system (Promega).
Preparation of probes and in situ hybridization
35
S in situ hybridization on paraffin sections was performed as previously described (Vainio et al., 1993) . The preparation of the following RNA probes has been described: Bsp, Msx2 Runx2 and Twist1 (Rice et al., 2003b) , Osteocalcin cDNA was inserted in pBluescipt KS+ vector and was digested with EcoRI for sense and Pst1 for antisense riboprobes, Osx (Yunker et al., 2004) . Both bright and dark field images were taken from hybridized sections. Silver grains were selected from the dark field image, colored red and then superimposed into the identical bright field image using Adobe Photoshop 6.0 software. Whole mount in situ hybridization was performed using digoxigenin-UTP-labeled riboprobes as previously described (Rice et al., 1997) .
Cell counting and statistical analysis
One way ANOVA and independent samples t-test were used for the statistical analysis of normal distributed samples. Non-parametric test Kruskal-Wallis and Mann-Whitney test were the chosen tests for non-normal samples. A P value of less than 0.05 was considered statistically significant. SPSS 14.0 was used for statistical analysis of the data.
Results
The developing mouse sagittal suture as a model of intramembranous bone growth E15.5 sagittal suture presents an excellent model to study osteogenesis as it is possible to see all stages of differentiating osteoblasts in a single tissue section. Expression profiles of different genes that indicate different stages in osteogenesis and suture patency were analyzed ( Fig. 1 ). Genes encoding a bone matrix glycoprotein Bone sialoprotein (Bsp) and a bone matrix gla protein Osteocalcin (Oc) were expressed by mature osteoblasts in the parietal bones ( Figs. 1A, B ). Runx2 and Osterix (Osx) are transcription factors that are essential for osteoblast development, and their expression is known to precede that of Bsp and Oc (Ducy et al., 1997) . Osx acts downstream of Runx2, it has an important role in the commitment of bipotential (chondrocyte/osteoblast) mesenchymal cells into the osteoblastic lineage (Nakashima et al., 2002) . Both Osx and Runx2 were expressed by early osteoblasts, and their expression was detected in the parietal bones and in the bone margins or osteogenic fronts. However, some Runx2 expression was detected in the sutural mesenchyme, suggesting that these cells, previously thought to be uncommitted, may have osteoblastic potential (Figs. 1C, D). The expression of Msx2 was restricted to the sutural mesenchyme and around the osteogenic fronts ( Fig. 1E ). Twist1 was expressed by a defined strip of mesenchymal cells in the suture with higher intensity near the osteogenic fronts which is consistent with its proposed role as a negative regulator of osteoblastic differentiation thus keeping the suture unossified. Twist1 was also detected in the dermis and epidermis (Fig. 1F ).
Based on these gene expression patterns and in our previous work (Rice et al., 2000 (Rice et al., , 2003a it is possible to determine the cellular identity and degree of differentiation of cells forming a suture based on their location in the developing suture. This makes the mouse E15.5 sagittal suture an uncomplicated and valuable model for intramembranous ossification and bone growth.
Proliferation is important for calvarial bone growth
We and others have previously shown that proliferation mainly takes place in the osteogenic fronts (Figs. 1G, G′) (Iseki et al., 1997; Liu et al., 1999b; Rice et al., 2003c) . In vivo calvarial bone growth can be mimicked in organ culture (Kim et al., 1998) . We cultured E15.5 calvarial explants in different concentrations of nocodazole (or DMSO as control) for 2 days. As nocodazole is an antimitotic drug that disrupts microtubules by binding to β-tubulin and arrests the cell cycle in G 2 /M phase (Jordan et al., 1992; Luduena and Roach, 1991) . Nocodazole is known to induce apoptosis in several normal and tumor cell lines (Wang et al., 1998) , we examined cell death in paraffin sections of the cultured calvarial explant and observed no differences in the number of apoptotic cells between nocodazole-treated and non-treated calvarial explants (data not shown). Whole mount in situ hybridization for Bsp was performed in order to help visualize the developing parietal bones. We observed patchy expression of Bsp, which is expressed by mature osteoblasts, in all the explants treated with the antimitotic drug. This prompted us to investigate whether nocodazole has an effect on osteoblast differentiation or whether patchy appearance of mature osteoblasts within the growing parietal bones was simply caused by reduced proliferation. We isolated mouse postnatal day 1 calvarial osteoblasts for primary cell culture. The cells were continuously treated with media containing nocodazole (0.1 μg/ml or 1.0 μg/ ml) (or DMSO in control samples) starting at three different time points: 1. After 1 day of culture: while control cells reached confluence and formed osteoblastic nodules, the nocodazoletreated cells did not reach confluence and did not form any nodules. 2. Cultured cells were treated with nocodazole only after cells had reached confluence. With low concentration of nocodazole osteoblastic nodules were formed but high concentration of nocodazole was toxic to the cells. This shows that nocodazole does not block osteoblastic differentiation. 3. Cultured cells were treated with nocodazole just when nodule formation was starting: nocodazole-treated cells formed small nodules (data not shown). These cell culture experiments showed that nocodazole does not have a direct effect on osteoblastic differentiation, rather it delays it only by reducing the level of cell proliferation, for instance not enough osteoblastic cells are produced with the window of time given for osteoblastic cell mass production before differentiation process is started during calvarial bone development and growth. The smaller size of nocodazole-treated nodules could also be explained by the fact that even in differentiated nodules, there is proliferation and it seems to be important for nodule formation (Malaval et al., 1999) . A reduction in parietal bone growth was also observed ( Figs. 2A-D) . We measured the distance between the parietal bones and found that nocodazole-treated explants had significantly wider sagittal sutures when compared to the controls, indicating reduced bone growth (P = 0.005). When comparing the growth during culture period (distance between parietal bones on day 0 minus distance between parietal bones after 2 days in culture) we observed that there had been a 19% reduction in parietal bone growth in the nocodazole-treated calvarial explants. Nocodazole significantly reduced cell proliferation compared to DMSO controls (P = 0.001). There were no statistically significant differences in cell proliferation between the different concentrations of nocodazole (P = 0.165, P = 1.000, P = 0.670) ( Figs. 2E-H) . Pooling data, proliferation was reduced by 44% in nocodazole-treated cultures in comparison to controls.
These results showed that nocodazole caused a reduction in cell proliferation and this correlated with reduced growth of the parietal bones. However, there was a discrepancy in these findings in that bone growth was not reduced to the same degree as the reduction observed in cell proliferation. This suggests that proliferation (and subsequent osteoblast differentiation) is an important mechanism whereby the calvarial bones grow but not the only one.
Sutural mesenchymal cells can differentiate into osteoblasts and become incorporated into the growing parietal bones
We performed sagittal suture mesenchyme grafting from green fluorescent protein (GFP) expressing mice into wild type sagittal suture calvarial explants. This experiment enabled us to follow the fate of the cells transplanted in the cultured calvaria ( Fig. 3) . Time lapse pictures of the tissues in culture (Figs. 3A-C, representative explant) showed the GFP positive mesenchyme transplanted into the calvaria (Figs. 3A′-C′). To locate the GFP-positive transplanted cells the cultured calvarial explants were sectioned. The tissue grafted was undifferentiated mesenchyme as explants harvested on day 0 showed no expression of the late osteoblast marker Bsp (Fig. 3E) or early osteoblast marker alkaline phosphatase (Figs. 3F-F″) . Hematoxylin and eosin staining in Fig. 3G shows a cross-section of a cultured sagittal suture. When this section was studied under fluorescent light (Fig. 3G′) we can identify the GFP-positive transplanted cells. A superimposition of Figs. 3G and G′ showed that most of the GFP-positive cells were pushed out of the suture and remained mesenchymal, but interestingly some of the GFP-positive cells were integrated into the parietal bone (Fig. 3G″, arrows) . To confirm that the GFP-positive cells, which had been incorporated into the parietal bone, had differentiated into osteoblasts, sections from grafted explants were hybridized with Bsp (Fig. 3H, representative section) . When the section shown in Fig. 3H was observed under fluorescent light (Fig. 3H′) , just as in Fig. 3H′ , GFP-positive cells were identifiable within the parietal bone. Thus GFPpositive cells, which were previously Bsp-negative and were located in the suture mesenchyme, were now located within the parietal bone and were Bsp-positive (Fig. 3H″) .
From this experiment we can conclude that firstly, calvarial explants healed after the grafting and the suture continued normal development, as shown by the parietal bone growth and a narrowing of the sagittal suture (Figs. 3A-C). Secondly, mesenchymal cells were excluded from the sutures as bones continued their growth (Figs. 3F″ and G″) . Thirdly, most of the transplanted mesenchymal cells remained in the mesenchyme, but some cells became located in the parietal bones (Figs. 3F′ and G′) . Taken together, a few sutural mesenchymal cells became incorporated into the parietal bone (6 out of 11 explants) (Figs. 3F, G) . The osteoblastic identity of these cells was confirmed by their expression of the osteoblast marker Bsp (Fig. 3G″, arrow) .
Cells within the osteogenic front can either remain in the advancing osteogenic front or become incorporated into the bone
As only a small portion of mesenchymal cells from the suture contributed to the parietal bones, the driving force for the expansion of these bones must lie within the proliferative osteogenic fronts. We hypothesized that cells in the osteogenic fronts undergo cell division in which some daughter cells remain at that location and differentiate into osteoblasts, while other daughter cells remain in the osteogenic front and are carried forward by this proliferation/differentiation process into the sutural space. To test this, we performed recombination experiments, transplanting GFP-positive tissue from an osteogenic front into the osteogenic front of the recipient calvarial explant to see if the GFP-positive cells remained within the osteogenic front or if they were integrated into the parietal bone. After 5 days of culture the transplant was integrated, and the two parietal bones had approximated normally (Figs. 4A-C) . The transplanted osteogenic front had moved with the developing parietal bone (Figs. 4A′-C′) . Explants were taken on day 0 of culture in order to assess the histological positioning of the graft (Figs. 4D-D″) . In Figs. 4E-E″, a representative 5-day culture shows GFP-positive osteogenic front cells that had stayed in the osteogenic front (Fig. 4E″, arrowhead) and also GFP-positive osteogenic front cells that had become incorporated into the parietal bone and were expressing the osteoblast marker Bsp (Fig. 4E″, arrow) . The small number of GFP-positive cells detected in Fig. 3E′ is due to the plane of section, this section being taken at the edge of the GFP positive graft. These results were confirmed by DiI-labeled cells in the osteogenic front (see below).
Sutural cells have different fate depending on their position within the suture
Vital dye injections were performed in order to make a fate map of the mesenchymal cells in the developing suture. Injections were performed in labeling cells in three different regions: (1) middle of the sagittal suture mesenchyme, (2) mesenchyme in the proximity of an osteogenic front, or (3) osteogenic front. Explants were cultured for 2 days and photographed daily. Interestingly, DiI-labeled cells did not move considerably. It appeared as if the DiI-labeled cells stayed in their original position and the developing bones approached them as their growth progressed (Figs. 5A-C″).
Labeled cells' fate was determined by analyzing tissue sections stained either for alkaline phosphatase (osteoblastic cells) or hematoxylin and eosin to aid localization.
The analysis of the tissues in which mid-sutural mesenchymal cells were labeled with DiI showed that all labeled cells remained undifferentiated. The osteogenic fronts grew into the area of the injected mesenchyme but none of these cells became incorporated into the bone (11 out of 11 explants) (Figs. 5D-D″). DiI-labeled mesenchymal cells located next to an osteogenic front were either localized in the mesenchyme or in the osteogenic front (7 out of 16 explants) ( Figs. 5E-E″) . Taken together, suture mesenchymal DiI injections indicated that mid-sutural cells were not destined to become osteoblasts during normal calvarial bone development and that only sutural cells next to the advancing osteogenic fronts could be incorporated into the growing bone.
To elucidate if the cells in the osteogenic front remained within the osteogenic front or if they became part of the parietal bone, we injected DiI directly into the osteogenic front. Tissue sections of these explants showed that some DiI-labeled cells had moved with the osteogenic front as it advanced , while other labeled cells were in the parietal bone after 2 days of culture (5 out of 13 explants) ( Figs. 5G-G″ arrowhead) . This supports the findings obtained with GFP tissue transplantations shown in Fig. 4 .
Discussion
Is intramembranous bone growth autonomous so that the initial condensed mesenchymal cell population keeps proliferating and differentiating into mature functioning osteoblasts without any assistance from the surrounding mesenchyme? Or do intramembranous bones grow by a combination of proliferation and recruitment of neighboring mesenchymal cells into the expanding bone?
Using mutant mouse lines we and others have shown previously that proliferation in the growing bones is essential for normal intramembranous growth and development (Rice et al., 2003c; Satokata et al., 2000) . Here we show that reducing cell proliferation by 44 percent in wild-type calvarial cultures results in a reduction in bone growth of only 19% (Fig. 2) . This discrepancy led us to study the involvement of the sutural mesenchyme in calvarial bone growth. We used tissue grafting to demonstrate that the majority of the surrounding mesenchyme was not incorporated into the calvarial bones. However a small proportion of mesenchymal cells were taken into the bones where they differentiated into functioning osteoblasts ( Figs. 3 and 4 ). This incorporation of mesenchymal cells into the developing calvarial bones cannot fully account for the remaining growth that occurs when proliferation is blocked. In our tissue culture experiments there will be a time-lag before the antimitotic drug is effective. During this time osteoprogenitors will continue to proliferate and then differentiate. Together with these cells, the explants will contain postmitotic osteoblasts which can lay down bone matrix and contribute to the lengthening of the bones. Another mechanism which may contribute to bone growth is the morphological changes that occur in the sagittal suture. The osteogenic fronts are folded endocranially, due in part to their location in the sulcus between cerebral hemispheres. Both in our tissue culture and in vivo the osteogenic fronts flatten leading to an extension of the bone margins and a narrowing of the sagittal suture.
To further study whether any mesenchymal cells from the suture can contribute to the bone, we performed vital dye injections into different sites in the suture. We found that, firstly, there does not appear to be any active, directional cell movement within the suture, even when close to the osteogenic fronts which express several potential chemoattractants. Labeled sutural cells radiated from the injection site to give the effect that some cells migrated away. However, this may be due to less and less dye being taken up by subsequent generations of cells in a proliferative environment. Secondly, calvarial bone growth appeared to be autonomous so that proliferation in the osteogenic fronts supplied sufficient cells needed for bone expansion and that this cell population 'pushed' forward into the sutural mesenchyme ( Fig. 5G″) . Thirdly, growing parietal bones can use sutural mesenchymal cells as building blocks but only if adjacent to the osteogenic fronts. The use of mesenchymal cells from the suture could be regarded as opportunistic: the sutural cells being in the right place at the right time.
By combining data from tissue grafting ( Figs. 3 and 4 ) and vital dye experiments (Fig. 5 ) with the analysis of molecular marker expression patterns in the developing suture (Fig. 1) , we observed that the majority of the sutural mesenchyme does not contribute to the parietal bones. This is a little surprising as a distinct band of cells stretching across the suture expresses the osteoblastic markers Runx2 and Msx2. Also, we have previously shown that undifferentiated mesenchymal cells possess pluripotency; being able, under specific in vitro conditions, to differentiate into several different cell types including osteoblasts (Grigoriadis et al., 1988) . One reason that these sutural cells do not more readily differentiate into osteoblasts may be because this population of cells also expresses Twist1. Twist1 binds to and negatively regulates Runx2 thereby inhibiting osteoblastic differentiation, and it has been proposed that Twist1 may have a role in keeping sutures patent (Bialek et al., 2004; Rice et al., 2000) . As Twist1 is not expressed by mature osteoblasts, sutural mesenchymal cells that become incorporated into the developing bones must stop expressing Twist1. Loss of TWIST1 function in humans causes the craniosynostosis syndrome Saethre-Chotzen (El Ghouzzi et al., 2001) . Runx2 determines the osteoblastic lineage from multipotent mesenchymal cells, enhancing osteoblast differentiation at an early stage and inhibiting osteoblast differentiation at a late stage (Komori, 2003) . Runx2 also regulates osteoblastic proliferation and lossof-function mutations in RUNX2 cause cleidocranial dysplasia which is characterized by disrupted skeletal development, most notably in the skull (Mundlos, 1999; Pratap et al., 2003) .
Signaling from the dura mater adjacent to a suture has been shown to be important in the control of suture patency (Kim et al., 1998; Opperman et al., 1995) . Tissue separation and recombination experiments have demonstrated that the orientation of the dura in relation to the suture is also important, with that regional differences regulating whether a suture closes at the appropriate time (Levine et al., 1998) . In our experiments, we dissected out the sutural mesenchyme together with its underlying dura mater and we maintained the orientation of the mesenchymal tissue transplanted in the host tissue.
What is the fate of the mesenchymal cells within the suture? Although some cells become incorporated into the calvarial bones, this would not account for the majority of the sutural mesenchyme. We have previously shown that there are clusters of apoptotic cells in the sutural mesenchyme but that this is a relatively uncommon event (Rice et al., 1999) . Using GFPpositive sutural tissue transplantation, we show that as bones grew towards each other most of the sagittal suture mesenchymal cells are expelled from the narrowing suture.
Also, the formation of a sutural blastema has been described (Markens, 1975) . This is a mesenchymal thickening that develops as intramembranous bones approximate (mouse E15.5-E17.5). This may, in part, be due to high levels of cell proliferation in the mesenchyme, concomitant with intense osteogenesis. However, it may also, in part, be explained by growth of the adjacent bones firstly compressing the mesenchyme between the osteogenic fronts and secondly expelling mesenchymal cells from their path, as we have observed in our explants (Fig. 3) .
In this study we have analyzed calvarial bone development under normal conditions. The next challenge will be to apply our findings to abnormal developmental situations such as the formation of sutural bones, craniosynostosis and delayed suture closure typified in cleidocranial dysplasia. Within developing sutures additional ossification centers can arise which eventually develop into small bones, called sutural or Wormian bones. Sutural bones most commonly occur in the lambdoid suture and are seen in a number of conditions including cleidocranial dysplasia, osteogenesis imperfecta and hypothyroidism (Gorlin et al., 2001; Hinton et al., 1984) . Sutural bones are also seen in Apert syndrome. Patients with Apert syndrome are characterized by several abnormalities including premature fusion of the coronal sutures. In addition, they present with a wide calvarial defect between the frontal and parietal bones. Within this region bony islands form in the calvarial mesenchyme, these later coalesce with each other and with the neighboring calvarial bones, resulting in the fusion across the midline and no further calvarial growth in this plane (Cohen and Kreiborg, 1996) . Under normal conditions we have shown that a small percentage of sutural mesenchymal cells are incorporated into the growing bones. However, during craniosynostosis or the formation of sutural bones the relative contribution of recruitment from the mesenchyme into the calvarial bones may be abnormally high.
During normal development the prime mechanism of calvarial bone expansion is by continued proliferation in the osteogenic fronts ( Fig. 6 ). As well as studying how intramembranous bones grow, we have also examined the fate of the sutural mesenchyme and found that cells have different fates depending on their location within the suture. Most mesenchymal cells remain undifferentiated in the suture, however a small proportion are recruited into the developing bones. We hope that these findings may help us understand the mechanisms of intramembranous ossification in general, which occurs not just in craniofacial bones but also in the periosteum of most bones during modeling and remodeling. Fig. 6 . Model for parietal bone growth and suture development. The primary mechanism for parietal bone growth is proliferation and subsequent differentiation of osteoprogenitors at the osteogenic fronts. In addition, sutural mesenchymal cells can differentiate into osteoblasts and become incorporated into the growing parietal bones, but only if adjacent to the osteogenic fronts. Thus the fate of calvarial mesenchymal cells varies depending on their position within the suture. Yellow figures represent the process of proliferation within the osteogenic front, in which osteoprogenitors in the osteogenic front undergo mitosis and remain within the osteogenic front. These cells move with the osteogenic front into the sutural mesenchyme as the two parietal bones approximate. Red figures represent the fate of preosteoblasts in the osteogenic front, which can either advance with the developing bone at its front or can terminally differentiate into mature osteoblasts and become incorporated in the parietal bone. Green figures represent the different fate of cells positioned in the sagittal suture: mesenchymal cells can either remain undifferentiated, getting expulsed from the suture as parietal bones grow towards each other, or they can become incorporated by the adjacent parietal bone and consequently express osteoblast marker genes as Bsp and AP. Neither of these two alternatives implicates cell migration, the basic movement is the parietal bone growth. of, osteogenic front.
